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The early identification of renal transplant recipients at
enhanced risk of developing acute and subclinical rejection
would allow individualized adjustment of
immunosuppression before functional graft injury occurs and
would exclude these patients from drug-weaning studies.
Protein and reverse transcriptase-polymerase chain
reaction-based analyses of candidate markers in urine open
the opportunity to closely monitor kidney-transplanted
patients non-invasively. The chemokine interferon-inducible
protein 10 (IP-10; CXCL10) might be an interesting candidate
to uncover ongoing immune processes within the graft.
Urine samples from kidney-transplanted recipients were
retrospectively analyzed for IP-10 mRNA and protein
expression. IP-10 levels were correlated with the incidence of
acute rejection episodes proven by histology and long-term
graft function assessed by the glomerular filtration rate 6
months post transplantation. IP-10 expression in urine
identified patients with ongoing acute rejection episodes
several days before a biopsy was indicated by rising serum
creatinine levels. Most importantly, elevated levels of urinary
IP-10 protein within the first four postoperative weeks were
predictive of graft function at 6 months even in the absence
of acute rejection. These data reveal a correlation between
elevated IP-10 expression in urine at early time points
post-transplantation and intragraft immune activation that
leads to acute rejection and compromised long-term graft
function.
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Acute rejection remains a serious and frequent complication
after renal transplantation although immunosuppressive
therapy and human leukocyte antigen matching have
improved tremendously in recent years. Both early diagnosis
and selective immunosuppressive therapy of acute rejection
are essential for the long-term outcome. Measurement of
serum creatinine (Cr) levels after renal transplantation is one
of the approved methods for monitoring allograft function.
However, the rise of serum Cr is a relatively late event of
intragraft injury. Therefore subclinical rejection events may
remain undiagnosed while untreated intragraft events
increase the risk of development of chronic allograft
nephropathy.1 Acute rejection is diagnosed by examination
of the immunological status of the graft by histological
analysis of percutaneous biopsies at times when severe
damage to the graft may have already taken place. The
procedure is not only laborious, time-consuming, and
expensive, but it can also lead to significant complications
that necessitate its replacement by non-invasive diagnostic
and prognostic assays.
Our group and others have shown by quantitative
polymerase chain reaction that urinary mRNA expression
of cytolytic molecules including Granulysin,2 Perforin, and
Granzyme B3 is associated with acute rejection. Recent
publications demonstrate that the expression of the CXC
chemokine interferon-inducible protein 10 (IP-10; CXCL10)
and its receptor CXCR3 in urine is significantly elevated
during kidney allograft rejection.4–6 Chemokines are small
peptides divided into C, CC, CXC, and CX3C families and
provide signals for the recruitment of different subsets of
T cells through seven-transmembrane-spanning, G-protein-
coupled receptors.7 CXCR3, a receptor predominantly
expressed by activated T- and natural killer cells, binds to
the three CXC non-ELR (glutamate–leucine–arginine) che-
mokines interferon-inducible T-cell-a chemoattractant
(CXCL11), IP-10 (CXCL10) and the monokine-induced by
g-interferon (CXCL9).8 It has been shown that CXCR3 is a
marker for T helper cells type-1 associated with inflam-
matory processes,9 and that IP-10 and monokine-induced
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by g-interferon (CXCL9) attract activated, but not resting T
cells.10,11 IP-10 expression in serum has been the subject of
several studies concerning autoimmune diseases including
rheumatoid arthritis,12 Hodgkin’s lymphoma,13 Graves’
disease,14 and multiple and systemic sclerosis.15–17 This
chemokine, which is secreted by a variety of cells including
monocytes, fibroblasts, and endothelial cells, plays an
important role during human solid-organ allograft rejec-
tion.18–21 An upregulation of IP-10 mRNA in human renal
allograft biopsies during acute rejection22 and a correlation
between elevated pre-transplant IP-10 serum levels and the
risk of severe rejection has also been described.23 In order to
develop a non-invasive diagnostic strategy for acute rejection
after renal transplantation, IP-10 mRNA5 and IP-10 protein
expression4 were analyzed in urine at the time of biopsy-
proven acute rejection. Elevated levels of IP-10 expression
correlated with the histological and clinical findings of
rejection in both studies.
Most studies performed on urine or biopsy samples
have relied on the measurement of IP-10 at the time of
biopsy-proven rejection. Early detection or even prognosis
of acute rejection prior to graft deterioration would be of
special value and could be achieved by follow-up screening
of patients post transplantation (Tx). To assess whether
IP-10 exhibits predictive properties of acute rejection, we
measured IP-10 mRNA expression in urine sediment and
IP-10 protein expression in free urine after renal trans-
plantation in a retrospective kinetic study. Firstly, we
examined not only whether the expression of this molecule
at the mRNA or protein level was increased at the time of
acute rejection diagnosis but whether elevations could be
observed before increased serum Cr indicated severe graft
injury due to effector cell infiltration. Secondly, we
addressed the question whether early intragraft immune
activation is related to long-term function. As the
glomerular filtration rate (GFR) is a good predictor of
long-term allograft function,24 we also ascertained whether
persistently elevated IP-10 levels in urine post Tx would
predict impaired kidney function as assessed by GFR
(o45 ml/min per 1.73 m2) at 6 months. Our data clearly
demonstrate the prognostic value of IP-10 protein
measurement after kidney transplantation for acute rejec-
tion diagnosis and that persistent elevation of IP-10
protein in urine is associated with limited graft function
at 6 months even in the absence of rejection.
RESULTS
Elevated levels of IP-10 mRNA in urine sediment after kidney
transplantation
To validate previous reports of heightened IP-10 expression
in patients with acute rejection, we analyzed the mean IP-10
mRNA expression of urine specimens from kidney trans-
planted recipients diagnosed with a Banff I–III (n¼ 21) or
borderline (BL) rejection episode (n¼ 14). In contrast to
patients with urinary tract infection or cytomegalovirus
(CMV) antigenemia, they showed significantly elevated levels
of IP-10 mRNA compared to controls with stable graft
function (n¼ 26) (Pp0.001) (Figure 1a).
Enhanced urinary IP-10 mRNA gene expression prior to acute
rejection
Because patients developing either an acute rejection episode
classified as Banff I–III or BL rejection demonstrated elevated
mRNA IP-10 expression, we further analyzed the predictive
value of urinary IP-10 mRNA monitoring in these patients.
Significantly upregulated urinary IP-10 mRNA levels could be
detected at all time points for patients diagnosed as acute
rejection (Banff I–III) and BL rejection compared to the
reference level of non-rejecting patients (Mann–Whitney
U-tests, Po0.05). Nevertheless, the receiver-operating char-
acteristic (ROC) -curve analysis of IP-10 mRNA expression
demonstrated very low sensitivities for all time-points. The
results for 6/7, 4/5, and 2/3 days prior to acute rejection
diagnosis are displayed in Figure 1b–d and in Table 1.
Elevated levels of IP-10 protein in urine sediment after
kidney transplantation
We further analyzed the mean IP-10 protein expression and
found significantly upregulated levels of IP-10 in urines from
patients diagnosed with Banff I–III (n¼ 26) or BL rejection
episode (n¼ 15) compared to controls (n¼ 41) (Po0.001)
confirming our previous observations made for IP-10 mRNA
measurement. Patients with urinary tract infection or CMV
infections showed no significantly elevated levels of urinary
IP-10 (Figure 2a).
Elevated IP-10 protein concentration in urine is predictive of
acute rejection
Because of insufficient sensitivity of IP-10 mRNA measure-
ment of urine sediment, we analyzed whether IP-10 protein
expression might be of higher statistical power. The ROC-
curve analysis for the three chosen time points prior to
biopsy were based on urine samples derived from patients
diagnosed with Banff I–III or BL rejection and revealed that
protein IP-10 levels were predictive of cellular acute rejection
already 6/7 days before biopsy-proven diagnosis. This result
corresponds with our observation made for mRNA expres-
sion. However, applying a cutoff value of about 200 pg/ml for
all time-points, the highest sensitivity of 71% and specificity
of 95% for urinary IP-10 measurement could be observed 2/3
days prior to biopsy (Figure 2b–d, Table 1). In general, mean
serum Cr of acute rejection patients was constantly elevated
at the indicated time points in contrast to mean IP-10
expression, which showed a strong dynamic regulation over
time (Figure 3).
As IP-10 protein expression in urine revealed a higher
sensitivity and specificity compared to IP-10 mRNA expres-
sion, we monitored urine samples derived from 35 patients
with biopsy-proven cell-mediated acute rejection from our
patient cohort for urinary IP-10 protein expression over 6
months post Tx in an individual case study. Twenty-seven
patients revealed significantly elevated levels of IP-10 during
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this observation period compared to the control group and
16 patients had significantly increased IP-10 protein con-
centrations in urine within a week before acute rejection was
diagnosed by histology. The kinetics of IP-10 protein
expression after Tx is shown for two representative patients
in Figure 4. Patient No. 1 was diagnosed for acute rejection
(Banff IIa) at day 17 post Tx (Figure 4a), and significantly
increased levels of IP-10 protein were already observed at day
10, 13, and 15 post Tx. Antirejection therapy with
methylprednisolone and treatment with OKT3 monoclonal
antibody starting at day 17 and 21, respectively, lead to a
marked reduction of serum Cr (o2 mg/dl) by day 29, but IP-
10 protein levels were still detectable at day 22 (1924 pg/ml)
and day 41 (949 pg/ml), suggesting persistent intragraft
immune activation. The patient was again treated with
methylprednisolone starting at day 44 post Tx, because of a
persisting acute rejection episode revealed by biopsy analysis
at day 48 (Banff IIa). At day 64 (1640 pg/ml), IP-10 protein
expression remained elevated but at 115 and 178 days post Tx
the patient displayed IP-10 levels within the range of the 95%
confidence interval.
Patient No. 2 was diagnosed with an acute rejection
episode (Banff III) at day 31 and at day 68 (Banff Ib) post Tx
(Figure 4b). Serum Cr declined after surgery, remained under
2 mg/dl until day 26 (1.73 mg/dl) and started to rise at day 27
(2.72 mg/dl). Interestingly, IP-10 protein expression was
already upregulated significantly prior to acute rejection
diagnosis by histology at day 19 post Tx (824 pg/ml) and
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Figure 1 | IP-10 mRNA expression in urine sediment after kidney transplantation. (a) The mean level of IP-10 mRNA expression in urine
sediment was significantly higher in patients with biopsy-proven rejection diagnosed as Banff I–III (n¼ 21; Po0.001) or BL (n¼ 14; P¼ 0.001)
compared to control patients with stable graft function (n¼ 26). There were no significant differences in IP-10 expression between control
patients and patients with urinary tract infection (UTI) (P40.05) or CMV antigenemia (P40.05). (b–d) ROC curves of urinary mRNA IP-10
expression levels analyzed for patients diagnosed with Banff I–III/BL rejection demonstrating the sensitivity and specificity for various cutoff
values for normalized IP-10 mRNA expression levels. Sensitivity defines true positive results and one-specificity true negative results for IP-10
mRNA in urine sediment as a predictive marker for acute rejection at the time points (b) 6/7 (Po0.05), (c) 4/5 (Po0.05), and (d) 2/3 (Po0.05)
days prior to biopsy-proven diagnosis of acute rejection. The mean control value was 0.0007 (2DCt ).
Table 1 | Predictive properties of urinary IP-10 mRNA and protein for acute rejection
mRNA Protein
Time point
(days prior to Rx) P Sens. (%) Spec. (%) AUC
Time point
(days prior to Rx) P Sens. (%) Spec. (%) AUC Cutoff (pg/m)
6/7 o0.05 58 85 0.731 6/7 o0.05 47 95 0.716 181.6
4/5 o0.05 50 85 0.686 4/5 o0.001 62 95 0.774 197
2/3 o0.05 53 85 0.681 2/3 o0.001 71 95 0.844 185
AUC, area under the curve; IP-10, interferon-inducible protein 10.
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increased up to 410 000 pg/ml at day 28. After onset of
antirejection treatment consisting of methylprednisolone and
OKT3, serum Cr levels decreased. In contrast, IP-10 protein
levels remained significantly elevated. A second biopsy on day
68 confirmed the persisting acute rejection episode, and
repeated treatment with methylprednisolone and OKT3 lead
to a rapid normalization of IP-10 protein expression and
serum Cr (o2 mg/dl). Both patients No. 1 and No. 2 did not
suffer from any urinary tract or CMV infections post Tx.
Elevated levels of IP-10 protein expression post Tx are
associated with restricted graft outcome
To investigate whether elevated IP-10 protein expression in
urine post Tx was predictive of graft function after 3 and 6
months, 67 patients were monitored for urinary IP-10
protein levels at six time points during the first month post
Tx defined as 0–1, 2–7, 8–13, 14–19, 20–25, and 26–31 days
post Tx and additionally once per month 2, 3, 4, 5, and 6 post
Tx. The multivariate, nonparametric analysis of longitudinal
data revealed a correlation between IP-10 concentrations in
urine after Tx and the 6 month GFR, allowing further
statistical investigations (Po0.05). Especially, the mean IP-10
protein expression during the first month post Tx revealed
significantly higher levels in urine of patients with a 6-month
GFR o45 ml/min per 1.73 m2 compared to patients with a 6
months GFR 445 ml/min per 1.73 m2 (Po0.05) (Figure 5a).
The evaluation of the predictive value of mean urinary IP-10
expression during the first month post Tx for a 6 month GFR
above or below 45 ml/min per 1.73 m2 revealed a sensitivity
of 58% and a specificity of 75% at a cutoff value of 196 pg/ml
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Figure 2 | IP-10 protein expression in urine after kidney transplantation. (a) The mean level of IP-10 protein expression in urine sediment
of patients with biopsy-proven episodes of acute rejection were significantly higher in patients diagnosed with Banff I–III (n¼ 26; Po0.001) or
BL (n¼ 15; Po0.001) compared to control patients with stable graft function (n¼ 41). There were no significant differences in IP-10 expression
between control patients and patients with urinary tract infections (P40.05) or CMV antigenemia (P40.05). (b–d) ROC curves of urinary IP-10
protein expression levels analyzed for patients diagnosed with Banff I–III/BL rejection. Sensitivity defines true positive results and one-specificity
true negative results for IP-10 protein in urine as a predictive marker for acute Rx at the time points (b) 6/7 (Po0.05, cutoff 182 pg/ml, 47%
sensitivity, 95% specificity), (c) 4/5 (Po0.001, cutoff 197 pg/ml, 62% sensitivity, 95% specificity), (d) 2/3 (Po0.001, cutoff 185 pg/ml, 71%
sensitivity, 95% specificity) days prior to acute rejection diagnosis by pathohistological examination of the graft. Mean expression of controls
was 31.8 pg/ml. UTI, urinary tract infection.
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Figure 3 | Dynamics of serum Cr and urinary IP-10 protein
concentrations prior to acute rejection. (a) IP-10 protein levels and
(b) serum Cr levels in urine are shown at the time points 6/7, 4/5, and
2/3 days prior to acute rejection diagnosis by pathohistological
examination of graft tissue (n¼ 28). Rx¼ rejection.
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(ROC-curve not shown, area under the curve was 0.68). To
investigate whether elevated levels of IP-10 during the first
month post Tx correlated with poor graft function
independently of acute rejection, IP-10 protein expression
of the patient group without any signs of clinical rejection
was analyzed separately. The analysis revealed a significant
induction (Po0.05) of IP-10 levels in those patients with
restricted kidney function after 6 months (n¼ 10, GFR
o45 ml/min per 1.73 m2) compared to patients with a well-
functioning graft (n¼ 24, GFR 445 ml/min) (Figure 5b). In
contrast, no significance could be estimated between elevated
IP-10 levels during the first month and a 3 months GFR.
DISCUSSION
Although acute rejection episodes have decreased because of
advanced clinical care and improved immunosuppressive
therapies, the development of new non-invasive diagnostic
strategies after renal Tx is still essential for a more
individualized therapy to optimize cost/benefit/risk ratios.
In particular, drug-weaning studies would benefit from early
identification of patients at enhanced risk of clinical and
subclinical rejection. Acute rejection episodes can lead to
severe and irreversible graft injury and the gold standard for
diagnosis is still the histological evaluation of graft tissue
obtained through the invasive procedure of needle biopsy.
Therefore, non-invasive monitoring of peripheral blood and
urine could lead to further diagnostic information regarding
the condition of the allograft at earlier time points and allow
antirejection therapy to be adjusted at an early stage before
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Figure 4 | Representative kinetic expression of IP-10 protein in urine. Arrows indicate time point of biopsy-proven acute rejection.
A confidence interval was calculated based on the arithmetic mean of IP-10 expression in 292 urine samples from patients with an
uncomplicated course. Columns represent IP-10 concentrations, the curve (E) shows serum Cr levels. (a) Patient No. 1 was diagnosed for
an acute rejection episode at day 17 post Tx (Banff IIa), which persisted and was proven again by biopsy histology post Tx at days 21 and 48.
(b) Patient No. 2 experienced biopsy-proven acute rejection episodes at days 31, 68, and 168 (Banff III, Ib, and 1a, respectively); ns, no urinary
sample available; nd, no detectable IP-10 levels.
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Figure 5 | Patients with an impaired 6 month graft function
reflected by a GFR o45 ml/min per 1.73 m2 demonstrate
significantly higher mean values of urinary protein expression
during the first month post Tx compared to patients displaying a
GFR 445 ml/min per 1.73 m2 independently of acute rejection.
(a) Analysis of patients with rejection episodes (BL, Banff I–III) and
stable graft function (Po0.05). (b) Separate analysis of patients
without signs of rejection (Po0.05).
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severe graft injury ensues. Chemokines participate in the
inflammatory response within allografts and it has become
clear that the interaction between the receptor CXCR3, which
is expressed by Th1 cells, and its ligand IP-10, leads to the
recruitment of activated T cells to sites of inflammation.25–29
Previous experimental studies indicate that the CXCR3
ligand IP-10 plays an important role in acute cardiac allograft
rejection30 and several clinical studies indicate an upregula-
tion of IP-10 gene22,31 and protein32 expression in renal
biopsies with allograft dysfunction. Recently, two groups
identified acute rejection processes after kidney transplanta-
tion non-invasively by measurement of IP-10 mRNA5 and
protein expression4 in urine. Elevation of chemokine
expression was correlated with the immunohistological
findings in allograft biopsies.
Our data support the findings of Hu et al.4 and Tatapudi
et al.5 that patients with acute rejection episodes have
significantly elevated urinary IP-10 mRNA and protein
expression compared to patients with stable graft function
(Figures 1a and 2a). In addition, the data presented show that
IP-10 gene and protein expression in urine of renal transplant
recipients is upregulated at earlier time points before invasive
needle biopsy is indicated by other clinical parameters like
rising serum Cr levels, suggesting IP-10 as a sensitive marker
for ongoing rejection (Rx) processes within the graft. The
statistical analysis (Mann–Whitney U-test) revealed that
patients with acute rejection episodes displayed significantly
upregulated IP-10 mRNA expression in urinary sediment up
to 7 days prior to biopsy compared to patients with stable
graft function (Po0.05). Since ROC-curve analysis of IP-10
mRNA expression in urine displayed low sensitivities (Figure
1b–d, Table 1), we also calculated the predictive properties for
IP-10 protein measurement prior to acute rejection and
found higher sensitivities and specificities for a defined cutoff
value of approximately 200 pg/ml (Figure 2b–d, Table 1).
Interestingly, it would have even been possible to diagnose an
ongoing rejection with a specificity of 100% several days
before biopsy applying a higher cutoff value as displayed in
Figure 2c and d. Mean IP-10 concentrations in urine of
patients with developing acute rejection episodes were
already higher 6/7 days prior to acute rejection compared
to urine samples obtained from control patients but rose
strongly over time in contrast to serum Cr levels, because of
immune activity within the graft (Figure 3).
The prognostic attributes of IP-10 expression for acute
rejection were further analyzed by performing individual
kinetic analyses of IP-10 protein levels in urinary samples
from patients with biopsy-proven acute rejection. This study
was performed to illustrate the feasibility of the assay for
individual monitoring in combination with other classical
clinical parameters. The data revealed significantly elevated
levels of IP-10 gene expression several days before histological
diagnosis of acute rejection, sometimes despite normal serum
Cr values. Onset of antirejection therapy, either with OKT3
monoclonal antibody or methylprednisolone led to a fast
decrease of IP-10 expression (Figure 4a–b). The majority of
samples from control patients with stable renal function
contained no or low levels of IP-10 protein.
GFR is usually accepted as the best overall index for
kidney function since Cr clearance is affected by factors like
renal tubular secretion, which results in overestimation of
graft function. We calculated the GFR for 3 and 6 months
post Tx in 67 patients by the Cockroft–Gault equation24 and
hypothesized that elevated urinary IP-10 expression at early
time points might be predictive of an impaired graft function
after 3 and 6 months (GFR o45 ml/min per 1.73 m2).
Multivariate analysis of the obtained data derived from urine
samples collected during the observation period confirmed
only a correlation between elevated IP-10 protein levels in
urine and a restricted graft function 6 months post Tx. In
contrast, no correlation could be found between a 3 months
GFR and IP-10 expression. We examined the mean IP-10
protein expression during the first month post Tx and found
that IP-10 levels in urine of patients with a GFRo45 ml/min
per 1.73 m2 were significantly higher than in patients with a 6
month GFR 445 ml/min per 1.73 m2 (Figure 5a). Moreover,
elevated mean IP-10 levels during the first month post Tx
were also predictive of impaired graft function even in the
absence of acute rejection (Figure 5b).
We suggest that an early induction of IP-10 in the graft
because of injury mediated by factors including prolonged
cold ischemia or surgical procedure leads to the attraction of
IFN-g-producing CXCR3þ cells. The release of IFN-g might
result in enhanced IP-10 production, which increases the
recruitment of activated leukocytes to the graft in a self-
sustaining loop. Therefore, we hypothesize that induction of
IP-10 mRNA and protein expression in urine could be an
early predictor of inflammatory changes within the graft
prior to acute rejection diagnosis and that it might be
predictive of ongoing (subclinical) immune activation
resulting in poor long-term graft function. This is supported
by the observation that elevated levels of IP-10 were not
related to the occurrence of urinary tract and CMV
infections.
Measurement of protein expression provides more
accurate evidence than mRNA expression analysis, while
urine collection and determination of IP-10 protein expres-
sion is simple, fast, and therefore clinically applicable. We
suggest that monitoring the IP-10 protein expression in urine
of renal transplant recipients may lead to early individualized
adjustment of immunosuppressive therapy and therefore
reduces the incidence of severe graft damage. In addition,
patients with enhanced IP-10 levels are less suitable to drug-
weaning procedures, particularly calcineurin inhibitors-free
protocols. To further evaluate this marker as a suitable
candidate for acute rejection screening approaches, it might
be of great interest to study IP-10 expression in other kidney
transplantation-associated complications including drug
toxicity or delayed graft function. Concerning the latter
issue, preliminary results from our laboratory indicate the
same predictive properties of urinary IP-10 protein expres-
sion for acute rejection independently of delayed graft
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function (data not shown). Moreover, simultaneous non-
invasive measurement of IP-10 with additional candidate
markers at early time points could increase the diagnostic
sensitivity and specificity of this approach leading to reduced
frequencies of biopsy procedures. We also suggest that the
prognostic properties of IP-10 make this molecule and its
receptor CXCR3 candidate targets for therapeutic interven-
tion with chemokine antagonists or receptor-blocking agents.
MATERIALS AND METHODS
Patients and sample collection
Adult renal transplant recipients were recruited from the Depart-
ments of Surgery and Nephrology, Virchow-Clinic, Universita¨tsme-
dizin Charite´, Germany between October 2002 and May 2004 and
provided informed consent. The study was approved by the local
ethical committee. Urinary samples of 100 ml were collected three
times/week/patient during hospitalization and twice/month from
outpatients. Immunosuppression consisted of methylprednisolone
and tacrolimus7mycophenolate mofetil and most patients addi-
tionally received anti-interleukin-2 receptormonoclonal antibody
induction. Histology was classified according to the Banff ’97
criteria33 and carried out by an experienced nephropathologist in
blinded fashion. Confirmed acute rejection episodes were treated
with methylprednisolone bolus or OKT3 monoclonal antibody. To
investigate whether elevated IP-10 expression is predictive for acute
cellular rejection, 54 patients were selected from our study cohort
and analyzed retrospectively. Thirty patients were diagnosed with an
acute cellular rejection (Banff I–III) and 24 patients who experienced
a needle biopsy after rising serum Cr levels were diagnosed with BL
rejection. They were also treated with methylprednisolone. Forty-
two renal-transplanted patients with stable graft function served as
controls. Patient demographics are summarized in Table 2.
Quantification of urinary mRNA gene expression
For mRNA expression analysis, urine was centrifuged at 10 000 r.p.m.
and 41C for 15 min. Pellets were washed in 1 ml phosphate-buffered
saline and centrifuged at 14 000 r.p.m. for 7 min at 41C. Supernatants
were discarded and total RNA was isolated from the pellet using the
Rneasys Mini Kit (Qiagen, Hilden, Germany). Samples were tested
for genomic DNA contamination and if tested positive were excluded
from the study. cDNA synthesis and real-time reverse transcriptase-
polymerase chain reaction of non-amplified mRNA were performed
as recently described.2 Gene expression of Histone mRNA was used
for normalization given by the formula 2DCt . All primers and probes
were designed using Primer Express software (Applied Biosystems,
Darmstadt, Germany).
Quantification of urinary IP-10 protein expression
For quantification of IP-10 protein expression, urine aliquots were
stored at 201C until measurement using an Enzyme-linked
immunosorbent assay Kit (HyCult Biotechnology, Beutelsbach,
Germany). For the individual kinetic studies, 302 samples from 35
patients with one or more acute rejection episodes were monitored
for IP-10 protein during the first 6 months following kidney Tx and
were compared to a confidence interval based on 292 control
samples derived from 41 patients with stable renal function.
GFR
For calculation of the predictive value of IP-10 protein levels in
urine for long-term function of the graft, the 3- and 6-month GFR
was estimated by the Cockroft–Gault equation.24 Samples were
divided into two groups of 35/31 patients displaying a 3/6-month
GFR of o45 ml/min per 1.73 m2 and 32/36 patients having a 3/6-
month GFR 445 ml/min per 1.73 m2. Out of the 67 investigated
patients, 33 suffered from a biopsy-proven cellular acute rejection.
The summary of patients displaying a good or restricted kidney
function reflected by a 3- and 6-month GFR 4/o45 ml/min per
1.73 m2 are summarized within Table 3.
Statistical analysis
Multivariate statistical analysis was performed using a Nonpara-
metric Analysis of Longitudinal Data (SAS-Macro by Brunner,
University Goettingen, Germany). ROC curves and Mann–Whitney
U-tests were performed applying SPSS 12.0 for Windows. Values of
Po0.05 were considered statistically significant. The calculation for
the overall normalized mRNA (2DCt ) and protein expression of IP-
10 was based upon the mean values of analyzed urines/patient with
acute rejection Banff I–III or BL rejection and one randomly chosen
sample/control patient with stable allograft function (mRNA,
n¼ 26; protein, n¼ 41). For evaluation of the predictive properties
of elevated IP-10 levels in urine, ROC-curve analysis of the
normalized IP-10 mRNA and protein expression data was
performed at three different time points defined as 2/3, 4/5, or 6/7
days before confirmation of acute rejection by pathohistological
analysis of biopsies. For IP-10 mRNA expression, 54 samples derived
from 32 patients with acute rejection were grouped into the three
time points specified above and compared to controls (n¼ 26). The
same set-up was chosen for IP-10 protein expression in urine
analyzing 57 samples from 29 patients with acute rejection episodes
and comparing them to controls (n¼ 41).
Table 2 | Demographics of kidney transplanted recipients analyzed in the study
Mean age Living/cadaveric
aRx Banff’97 (grade)
Patients (n) Male/female (years) donor First transplant Retransplant BL I II III
aRx 54 36/18 49715 7/47 48 6 24 18 11 1
nRx 42 19/23 54713 9/33 35 7
aRx, acute rejection episodes; BL, borderline; nRx, stable graft function.
Table 3 | Number of patients analyzed for IP-10 protein
expression up to 3 and 6 months post Tx
aRx (n=33) w/o Rx (n=34)
GFR o45 ml/mi/1.73 m2
3 months (n=35) 24 11
6 months (n=31) 21 10
GFR 445 ml/min/1.73 m2
3 months (n=32) 9 23
6 months (n=36) 12 24
aRx, acute rejection episodes; glomerular filtration rate; IP-10, interferon-inducible
protein 10; nRx, stable graft function.
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